Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ATHE Alterity Therapeutics Limited daily Stock Chart
ATHE [NASD]
Alterity Therapeutics Limited
Healthcare | Biotechnology | Australia
statements
Index- P/E- EPS (ttm)-0.69 Insider Own18.70% Shs Outstand14.47M Perf Week-8.33%
Market Cap29.63M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float9.96M Perf Month134.43%
Income-8.80M PEG- EPS next Q- Inst Own2.10% Short Float0.07% Perf Quarter122.74%
Sales- P/S- EPS this Y-29.30% Inst Trans- Short Ratio0.00 Perf Half Y83.33%
Book/sh0.54 P/B2.65 EPS next Y- ROA-75.20% Target Price- Perf Year14.40%
Cash/sh- P/C- EPS next 5Y- ROE-92.30% 52W Range0.28 - 2.35 Perf YTD83.33%
Dividend- P/FCF- EPS past 5Y8.40% ROI- 52W High-37.87% Beta1.13
Dividend %- Quick Ratio4.40 Sales past 5Y- Gross Margin- 52W Low421.43% ATR0.17
Employees15 Current Ratio4.40 Sales Q/Q-23.50% Oper. Margin- RSI (14)68.60 Volatility6.72% 11.82%
OptionableNo Debt/Eq0.00 EPS Q/Q4.10% Profit Margin- Rel Volume0.20 Prev Close1.43
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.96M Price1.46
Recom- SMA2045.84% SMA5089.90% SMA20079.32% Volume46,864 Change2.10%
Jul-01-20 08:12AM  
The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes
Benzinga +57.14%
Jun-29-20 11:14PM  
Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
PR Newswire
May-20-20 08:58PM  
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
PR Newswire
Apr-30-20 04:35AM  
Alterity Therapeutics Limited Releases Its Appendix 4C - Q3 FY20 Quarterly Cash Flow Report
PR Newswire
Apr-21-20 05:50PM  
How Should Investors React To Alterity Therapeutics Limited's (ASX:ATH) CEO Pay?
Simply Wall St.
Feb-21-20 07:15PM  
Imagine Owning Alterity Therapeutics (ASX:ATH) And Trying To Stomach The 86% Share Price Drop
Simply Wall St. -5.21%
Nov-11-19 10:30PM  
Companies Like Alterity Therapeutics (ASX:ATH) Can Be Considered Quite Risky
Simply Wall St.
Sep-12-19 11:07PM  
Does Alterity Therapeutics Limited's (ASX:ATH) CEO Salary Reflect Performance?
Simply Wall St.
Jul-29-19 08:00AM  
Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial
Business Wire
Jul-11-19 09:31PM  
Imagine Owning Alterity Therapeutics (ASX:ATH) And Trying To Stomach The 89% Share Price Drop
Simply Wall St. -6.30%
May-06-19 08:00AM  
Initial Data for Alterity Therapeutics Phase 1 Clinical Trial Released at American Academy of Neurology Annual Meeting
Business Wire -5.38%
May-03-19 08:00AM  
Alterity Therapeutics Presents at the American Academy of Neurology Annual Meeting
Business Wire +14.81%
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment of Parkinson's disease and other movement disorders. It is also developing PBT2 for patients with Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.
open in yahoo | open in reuters | open in google